Indian company Aurobindo Pharma has acquired four cell culture-derived biosimilar products from Swiss-based TL Biopharmaceutical.

Under the agreement, TL will supply all the developmental data for four molecules and the products will be globally developed, commercialised and marketed by Aurobindo and its affiliates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Three out of the four biosimilars are monoclonal antibodies in oncology.

Regulatory filing for these products is expected during 2020-22.

Aurobindo Pharma managing director Govindarajan said: “We are impressed with TL’s product development as these are developed to the highest standards of biosimilarity.

“This acquisition is in-line with our strategy of investing in complex products portfolio.”

“We are impressed with TL’s product development as these are developed to the highest standards of biosimilarity.”

With this acquisition, Aurobindo will be able to prepare to take its lead molecule, a Bevacizumab biosimilar, for clinical trials this year.

Anti-antiogenesis drug Bevacizumab is used to treat multiple cancers, including metastatic colon or rectal cancer, non-squamous and non-small-cell lung cancers.

Aurobindo stated that the transaction is a strategic investment for future growth.

The company will build on these first four products licensed from TL and plans to expand its diverse portfolio of eight more next wave biosimilars.

A fully functional R&D centre for biologics development is already in place and the company is also further planning to establish a new manufacturing facility in Hyderabad, India, which is expected to be ready by the second quarter of next year.